Filana Therapeutics, Inc.
No trades
No trades
Price target
6.500.000.00%
The 2 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 2 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
The current price of FLNA is 0.9950 USD — it has decreased by −0.44% in the past 24 hours. Watch Filana Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Filana Therapeutics, Inc. stocks are traded under the ticker FLNA.
FLNA stock has fallen by −0.60% compared to the previous week, the month change is a −26.55% fall, over the last year Filana Therapeutics, Inc. has showed a −57.84% decrease.
We've gathered analysts' opinions on Filana Therapeutics, Inc. future price: according to them, FLNA price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch FLNA chart and read a more detailed Filana Therapeutics, Inc. stock forecast: see what analysts think of Filana Therapeutics, Inc. and suggest that you do with its stocks.
FLNA reached its all-time high on Jul 14, 2000 with the price of 184.5696 USD, and its all-time low was 0.7600 USD and was reached on Dec 24, 2018. View more price dynamics on FLNA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
FLNA stock is 9.98% volatile and has beta coefficient of 1.66. Track Filana Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Filana Therapeutics, Inc. there?
Today Filana Therapeutics, Inc. has the market capitalization of 48.07 M, it has decreased by −8.23% over the last week.
Yes, you can track Filana Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Filana Therapeutics, Inc. is going to release the next earnings report on Nov 11, 2026. Keep track of upcoming events with our Earnings Calendar.
FLNA earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.23 USD resulting in a 20.00% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Filana Therapeutics, Inc. earnings.
Filana Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
FLNA net income for the last quarter is −8.60 M USD, while the quarter before that showed −10.33 M USD of net income which accounts for 0.00% change. Track more Filana Therapeutics, Inc. financial stats to get the full picture.
No, FLNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 8, 2026, the company has 20 employees. See our rating of the largest employees — is Filana Therapeutics, Inc. on this list?
Like other stocks, FLNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Filana Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Filana Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Filana Therapeutics, Inc. stock shows the sell signal. See more of Filana Therapeutics, Inc. technicals for a more comprehensive analysis.